OPEN ACCESS pISSN 2234-3806
eISSN 2234-3814

Table. 2.

Table. 2.

Summary of the cost and outcome results in the analysis

Results Tissue-only strategy T issue-first strategy Plasma-first strategy
First-line treatment of advanced NSCLC
Sensitizing mutation treated (%) 84.6 92.5 96.8
Cost (KRW)
Total 1,543,367 1,564,432 1,004,283
Biopsy 676,066 676,066 140,960
Complication 55,067 55,067 11,481
EGFR testing 131,505 144,656 158,924
Second-line treatment of advanced NSCLC
Overall survival (months) 25.0 24.9 25.9
Progression-free survival (months) 9.1 9.1 9.6
T790M mutation treated (%) 83.2 82.2 91.7
No. of biopsies 1.1 1.0 0.3
Cost (KRW)
Total 165,815,059 164,137,642 179,382,572
Biopsy 743,672 676,066 230,538
Complication 60,573 55,067 18,778
EGFR testing 144,656 144,656 176,348

Abbreviations: NSCLC, non-small cell lung cancer; KRW, Korean won; EGFR, epidermal growth factor receptor.

Ann Lab Med 2023;43:605~613 https://doi.org/10.3343/alm.2023.43.6.605

© Ann Lab Med